CASI Pharmaceuticals (CASIF) Interest & Investment Income (2022 - 2025)
CASI Pharmaceuticals (CASIF) reported Interest & Investment Income of $636000.0 for Q3 2025, up 208.53% on a YoY basis from $206137.2 in Q3 2024, and up 244.22% quarter-over-quarter from -$441000.0 in Q2 2025.
CASI Pharmaceuticals (CASIF) Interest & Investment Income (2022 - 2025) Analysis & Trends
CASI Pharmaceuticals has reported Interest & Investment Income for 4 years, with the latest figure at $636000.0 in Q3 2025.
- For the quarter ending Q3 2025, Interest & Investment Income rose 208.53% year-over-year to $636000.0; the trailing twelve-month figure through Sep 2025 stood at $636000.0 (up 208.53% YoY), and the FY2025 full-year result was -$840000.0, up 3.56% from the prior year.
- Interest & Investment Income for Q3 2025 stood at $636000.0, up from -$441000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $636000.0 in Q3 2025, with the low at -$871000.0 in Q4 2024.
- Historically, Interest & Investment Income has averaged -$137000.0 across 4 years, with a median of -$192000.0 in 2024.
- Annual changes were most pronounced in 2023 — Interest & Investment Income jumped 397.03% — and 2024, when it tumbled 5706.67%.
- CASI Pharmaceuticals' Interest & Investment Income stood at -$62000.0 in 2022, then jumped by 75.81% to -$15000.0 in 2023, then plunged by 5706.67% to -$871000.0 in 2024, then soared by 173.02% to $636000.0 in 2025.
- The last three Interest & Investment Income figures came in at $636000.0 (Q3 2025), -$441000.0 (Q2 2025), and -$197000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | 597,319.59 |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | - |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | 305,000.00 |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | - |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | -14.79 Mn |
| 10 | CASI Pharmaceuticals | - | - | 3.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 636,000.00 |
| Jun 30, 2025 | -441,000.00 |
| Mar 31, 2025 | -197,000.00 |
| Dec 31, 2024 | -871,000.00 |
| Sep 30, 2024 | -586,000.00 |
| Jun 30, 2024 | -382,000.00 |
| Mar 31, 2024 | -192,000.00 |
| Dec 31, 2023 | -15,000.00 |
| Sep 30, 2023 | 502,000.00 |
| Dec 31, 2022 | -62,000.00 |
| Sep 30, 2022 | 101,000.00 |